Needham Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer maintains a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and raises the price target from $60 to $63.
November 01, 2023 | 4:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst maintains a 'Buy' rating on Apellis Pharmaceuticals and raises the price target from $60 to $63, indicating positive sentiment towards the stock.
The raised price target by Needham analyst indicates a positive outlook for Apellis Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100